March 18th 2023
From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.
March 15th 2023
March 11th 2023
March 9th 2023
Childhood Trauma and Outcomes With Lithium or Quetiapine in Outpatients With Bipolar DisorderDecember 8th 2022
Does childhood trauma affect outcomes in bipolar disorder? Researchers analyzed the impact of childhood trauma on outcomes in outpatients with bipolar disorder treated with lithium or quetiapine in a randomized clinical trial.
Phase 3 Trial of Dexmedetomidine for Bipolar I or II, Schizophrenia Doses First ParticipantsNovember 30th 2022
The phase 3 SERENITY III trial investigating at-home use of dexmedetomidine (BXCL501) sublingual film for agitation associated with bipolar I or II disorder or schizophrenia has started.
Lithium and Suicide Prevention: More Thoughts on Recent VA StudyOctober 14th 2022
"Despite this new study and the need for further research, the best recommendation at this time regarding lithium in patients with bipolar disorder who are suicidal would be to consider it a worthwhile option."
Calcium-Channel Blocker and Adenosine Modulator Use and Risk of Hospitalization in Bipolar DisorderOctober 5th 2022
Researchers performed a nationwide cohort study of the use of calcium-channel blockers and adenosine modulators and risk of hospitalization in bipolar disorder.
Assessment of Individuals With Older Age Bipolar DisorderSeptember 28th 2022
Between 1980 and 1998, the relative frequency of late-onset bipolar disorder increased from 1% to 11%. How can you best assess for this condition?